Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

American multinational biopharmaceutical firm Bristol Myers Squibb (BMS) has hosted a high-level professional forum in partnership with the U.S. Embassy in Hungary, titled “Innovating Together for ...

Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major industry names such as Arch Venture Partners and Bristol Myers Squibb Co. With ...

In a major setback to Zydus Lifesciences, the Delhi High Court has restrained the company from launching its proposed ...

Newleos is announcing a new member of its Board of Directors and the initiation of Phase 1b clinical studies with NTX-1955 in ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

Shares of Bristol Myers Squibb Co. BMY advanced 2.00% to $48.98 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement ...

Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach. | Dispatch Bio has unveiled with $216 million and ...